Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
Innovative GFAP blood biomarker test expands
The new GFAP test – a first-of-its-kind test to be offered commercially nationwide – offers physicians a more efficient pathway to assess the presence and progression of neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, glioblastoma and injuries like traumatic brain injury (TBI). The biomarker test also expands on
"The introduction of the GFAP biomarker test marks a significant milestone for
The GFAP test utilizes highly sensitive immunoassay technology to measure the presence of GFAP from a simple blood draw, which can be conducted in hospitals, a physician's office or any of
GFAP typically exists in the brain's support cells, known as astrocytes. In the context of neurodegenerative disease or injury, astrocytes release GFAP into the blood, allowing brain injury and disease to be assessed through a simple blood draw. GFAP has been widely studied as a valuable early-stage indicator of neurological damage.
For more information about the GFAP test and its applications in patient care, please visit https://www.labcorp.com/tests/484430/glial-fibrillary-acid-protein-gfap-serum
About
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-announces-first-of-its-kind-test-for-early-indication-of-neurodegenerative-diseases-and-brain-injuries-using-a-blood-draw-302116574.html
SOURCE
Media: Kimbrel Arculeo, 336-436-8263, [email protected]; or Investors: Christin O'Donnell, 336-436-5076, [email protected]